Niagen Bioscience, Inc.·4

Feb 24, 4:47 PM ET

Lopez Carlos Luis 4

4 · Niagen Bioscience, Inc. · Filed Feb 24, 2026

Research Summary

AI-generated summary of this filing

Updated

Niagen (NAGE) SVP Carlos Lopez Receives 41,420-Share Award

What Happened Lopez Carlos Luis (SVP, General Counsel) received a grant/award (transaction code A) of 41,420 derivative shares on 2026-02-19. The award shows $0 cash paid per share (no exercise price reported), so this was an equity compensation grant rather than a market purchase or sale.

Key Details

  • Transaction date: 2026-02-19; Filing date: 2026-02-24 (filed five days after the transaction; exceeds the 2-business-day Form 4 deadline and appears late by one business day).
  • Shares granted: 41,420 derivative shares; reported price: $0.00 (no cash consideration reported).
  • Vesting: Footnote indicates one-fourth of the shares vest on each anniversary of the grant date (25% per year over four years).
  • Shares owned after transaction: Not disclosed in the provided excerpt — see the full Form 4 for total holdings and other holdings of derivative securities.

Context This was an equity compensation award (derivative grant) for an executive — common for executive pay and retention. Such awards are not an immediate purchase signal; vesting conditions mean the shares will be earned over time. The late filing is a compliance detail; it does not by itself indicate intent or sentiment.

Insider Transaction Report

Form 4
Period: 2026-02-19
Lopez Carlos Luis
SVP, General Counsel
Transactions
  • Award

    Employee Stock Options (right to buy)

    [F1]
    2026-02-19+41,42041,420 total
    Exercise: $4.94From: 2027-02-19Exp: 2036-02-18Common Stock (41,420 underlying)
Footnotes (1)
  • [F1]One-fourth of the shares subject to the option shall vest on each anniversary of the grant date.
Signature
/s/ Jeong James Lee, Attorney-in-Fact|2026-02-24

Documents

1 file
  • 4
    wk-form4_1771969645.xmlPrimary

    FORM 4